Creating VaCCines, ProteCting Life

Transcription

1 Creating VaCCines, ProteCting Life

2 PreVenting Disease through VaCCination a Constant BattLe Immunization has been a great public health success story. The lives of millions of children have been saved, millions have the chance of a longer healthier life Vaccination is a benefit to mankind. Nelson Mandela, winner of the Nobel Peace Prize, 1993 From the moment Louis Pasteur administered the first rabies vaccine in 1885, Sanofi Pasteur has drawn inspiration from the legacy of its founders to protect people from infectious diseases. Each year, our company makes it possible to vaccinate more than 500 million people across the globe. Vaccination campaigns are highly successful when people are afraid of lifethreatening infections but, over time, the fear of the disease fades and vaccine coverage tends to decline. This is why we have made a long-term commitment, one that is part of a global, collaborative vaccination policy. The challenges are to increase vaccine coverage and develop new vaccines. Ensuring that vaccination remains a frontline healthcare intervention requires a concerted effort by national and international health authorities and by all healthcare professionals. Beyond development and production, Sanofi Pasteur is committed to improving access to vaccines with: specially adapted packaging and a tiered pricing policy to facilitate access in the poorest countries production facilities in close proximity to local needs, for example, in India, China and Mexico support for local healthcare infrastructures. For example, the EPIVAC and PREVAC Plus programs train physicians and paramedical personnel on the vaccination systems in Central and Western African countries. polio on the verge of eradication Since the creation of the Global Polio Eradication Initiative (GPEI) in 1988, polio cases have decreased by over 99% worldwide (3) thanks to an unprecedented cooperative action involving 200 countries and 20 million volunteers (4). The hope may now become a reality in just a few years: polio is on target to become the second disease to be eradicated from the face of the earth. Sanofi Pasteur, the world s leading provider of inactivated polio vaccine, is also the largest corporate donor to GPEI. (3) who fact sheet no. 114 october 2011 (4) gpei about us at a glance: the global polio eradication initiative before a vaccination campaign eliminated smallpox in 1980, the disease threatened 60 percent of the world s population and killed one out of four victims (1). worldwide, annual seasonal influenza epidemics result in three to five million cases of severe illness and 250,000 to 500,000 deaths (2). (1) who fact sheet no. 288 march 2005 (2) who, fact sheet no. 211 april 2009

3 the LeaDer in PreVenting infectious Diseases sanofi PasteUr, the VaCCines DiVision of sanofi _ 3,469 million in revenue in 2011 THE WORLD s LeaDing PROVIDER of seasonal influenza vaccines and the world s leading supplier of inactivated polio vaccines THE LARGEST PRODUCT Range available against 20 bacterial or viral Diseases 15 PRODUCTiOn and/or R&D sites operational or under construction, in France, the United States, Canada, Argentina, China, India, Thailand and Mexico 13 VaCCines in development More than to meet the specific needs of different populations (new vaccines or improvements to existing vaccines) 1billion doses of vaccines produced each year 13,000 EmPLOyEES worldwide

4 innovation & ProDUCtion an ongoing CHaLLenge the development of a new vaccine can take 14 (5) to 25 (6) years and can cost between $300 million and $1 billion (5). The increasing population, the efforts to improve health worldwide, and the emergence of new diseases all contribute to the mounting need for vaccines. Global demand is rising steadily and can only be met through a combination of innovation and large quantity production. We therefore continually invest in research and development, as well as in the expansion of our production facilities. Sanofi Pasteur has focused closely on production capacity in an effort to make large quantities of vaccines available that meet the highest quality standards. More than 50 percent of our employees are dedicated to industrial operations. We invest more than 1 million in research and development every day. Our priorities are in new vaccines, improvements to existing vaccines, new combination vaccines (particularly for children), administration systems, etc. (5) wilde h. what are today s orphaned vaccines? clinical infectious diseases 2001; 33: by the infectious diseases society of america. (6) tomich n, ed. the global vaccine shortage: the threat to children and what to do about it. new canaan, conn: the albert b. sabin vaccine institute; 2003:26. To be at the forefront of innovation, Sanofi Pasteur has entered into a number of partnership agreements with universities, prestigious research institutes and innovative biotechnology companies. Our teams are working on a number of major projects, including the development of vaccines against dengue fever and certain hospital-acquired infections, such as Clostridium difficile. The vaccine developed by Sanofi Pasteur against the Clostridium difficile bacterium is now in phase II clinical trials. The alarming spread of hospital-acquired infections in Europe and the United States over the last ten years has accelerated the research and development efforts. AN END TO THE DENGUE THREAT IS IN SIGHT Since 1990, Sanofi Pasteur has been working to develop a vaccine against dengue fever, a mosquito-borne viral infection that affects million people each year and poses a threat to nearly half the global population (7). Sanofi Pasteur s tetravalent vaccine, which is the first to reach phase III clinical development and targets all four serotypes of the dengue virus, should be available in (7) cdc centers for disease control and prevention dengue

5 ALTHOUGH IMMUNIZATION SAVES MORE THAN 3 MILLION LIVES EACH YEAR, 3 MILLION PEOPLE STILL DIE DUE TO LACK OF ACCESS TO VACCINES (8). OUR VISION is of a world in which no one suffers or dies from a vaccine-preventable disease. (8) who

6 CIRC.12/01/COM/ Sanofi Pasteur - Photos : Y. Arcurs - Fotolia ; A. Chézière ; Distinctive Images Fotolia ; P. Dolémieux ; N. Domy ; J. Fotso ; R. Monceaux ; V. Moncorgé ; V. Védrenne - SANOFI PASTEUR S.A. au capital de RCS Lyon B Code APE 2120 Z Printed by Entreprise Adaptée ANAIS on 100 % recycled paper WORLDWIDE, OUR VACCINES PROTECT AGAINST: chickenpox, cholera, diphtheria, type b infections, hepatitis a, hepatitis b, influenza, japanese encephalitis, measles, meningococcal meningitis (serogroups a, c, Y and w-135), mumps, pertussis, pneumococcal infections, poliomyelitis, rabies, rubella, tetanus, tuberculosis, typhoid fever, Yellow fever SANOFI PASTEUR Headquarters, 2 avenue Pont Pasteur, Lyon cedex 07, France